Charles Schwab
CYCN icon

Charles Schwab’s Cyclerion Therapeutics CYCN Stock Holding History

Charles Schwab’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-775
Closed -$27K – 3594
2021
Q4 		$27K Hold
775
– – ﹤0.01% 3562
2021
Q3 		$48K Sell
775
-5,706
-88% -$373K ﹤0.01% 3456
2021
Q2 		$506K Sell
6,481
-3,503
-35% -$219K ﹤0.01% 3165
2021
Q1 		$558K Buy
9,984
+1,129
+13% +$84.8K ﹤0.01% 3037
2020
Q4 		$542K Sell
8,855
-616
-7% -$42K ﹤0.01% 2962
2020
Q3 		$1.15M Buy
9,471
+2,983
+46% +$341K ﹤0.01% 2640
2020
Q2 		$767K Buy
6,488
+1,146
+21% +$95.8K ﹤0.01% 2702
2020
Q1 		$284K Buy
5,342
+70
+1% +$4.99K ﹤0.01% 2911
2019
Q4 		$287K Sell
5,272
-359
-6% -$33.5K ﹤0.01% 2984
2019
Q3 		$1.36M Buy
5,631
+649
+13% +$140K ﹤0.01% 2494
2019
Q2 		$1.14M Buy
+4,982
New +$1.41M ﹤0.01% 2535

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Charles Schwab's CYCN Position: Q1 2022 in Review

Charles Schwab sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 775 shares — an estimated $27K sold.

Charles Schwab first reported a position in CYCN in Q2 2019 and held it in 11 quarters. The position peaked at $1.36M in Q3 2019. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

  • Charles Schwab reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 775 Cyclerion Therapeutics shares in Q1 2022, an estimated $27K.
  • Charles Schwab first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 11 quarters.
  • Charles Schwab's Cyclerion Therapeutics position peaked at $1.36M in Q3 2019.
  • 50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.